Loading organizations...
Loading organizations...
Guava is a technology company.
Guava provides a specialized financial and community platform for Black entrepreneurs and small business owners. It offers a banking hub and a private network, fostering connections via Supper Club dinners and a digital community. This approach facilitates access to capital, expands market reach, and cultivates collaborations.
Kelly Ifill founded Guava in 2020, recognizing Black founders needed dedicated financial services and a supportive professional network. Her background, including a Columbia Business School instructional role, informs the company's strategic development of solutions addressing systemic barriers within this demographic.
The platform empowers Black entrepreneurs and small business owners with tailored growth resources. Guava’s vision focuses on building a powerful engine for community and business development, ensuring members possess tools and connections for lasting success. It fosters a thriving ecosystem.
Guava has raised $2.6M across 2 funding rounds.
Guava has raised $2.6M in total across 2 funding rounds.
Guava Technologies is a privately-held biotechnology and medical device company that develops and manufactures innovative flow cytometry systems and cell analysis tools for life scientists.[1][2] These Personal Cytometers enable rapid, accessible analysis of single cells without sheath fluid, addressing challenges in genomics, proteomics, and drug discovery by providing affordable, user-friendly solutions akin to personal computing for cell biology.[2] The company targets cell biologists in research and bioprocessing, solving the need for quick, precise cellular assays that were previously complex and inaccessible.[2]
While multiple entities share similar names—including GuavaTech (IT trading solutions for financial markets)[3] and Guava Technology, Ltd (a UK-registered firm founded in 2022 by entrepreneurs Jonah and Jordan Burglin and Jonathan Vieira)[5]—the query aligns most closely with the biotech firm known for its cytometry innovations.[1][2]
Guava Technologies emerged at the intersection of advances in genomics and proteomics, which generated vast cellular data but lacked tools for rapid single-cell analysis.[2] Founded in the early 2000s (with a valuation of $22.6M by February 2009), the company was chaired by Dr. Nagesh Mhatre, who emphasized "solutions that are just a click away" for life scientists.[2] Its Personal Cytometer platform, featuring novel fluidics, expandable software, and application-specific reagents, marked a pivotal innovation by eliminating sheath fluid needs and establishing strong IP.[2]
Early traction built on this "personal cytometry" vision, revolutionizing access for individual researchers much like PCs democratized computing.[2] The company progressed through funding rounds and was ultimately acquired (latest on October 18, 2018), reflecting its impact in bioprocessing tools.[4]
Guava Technologies rode the early 2000s wave of genomics and proteomics booms, where data abundance outpaced analysis tools, making single-cell insights critical for drug discovery and basic research.[2] Its timing capitalized on the shift toward accessible biotech instrumentation, mirroring the PC revolution by empowering non-experts with cytometry power.[2] Market forces like rising demand for rapid cellular assays in biopharma favored its sheathless, cost-effective systems, influencing the ecosystem by lowering barriers for cell biologists and accelerating workflows in a field dominated by bulky, expensive equipment.[1][2]
Competitors like Plectix BioSystems and IntelCell focused on related cell signaling or culture tools, but Guava's personal-scale cytometry carved a niche in democratizing high-throughput analysis.[4]
Post-acquisition (2018), Guava Technologies' legacy endures in modern flow cytometry, with its innovations likely integrated into broader biopharma tools amid ongoing single-cell sequencing trends.[4] Next steps could involve AI-enhanced analytics or expanded multi-omics integration, shaped by precision medicine and automated bioprocessing growth. Its influence may evolve through licensed tech, amplifying accessible cell analysis in a market projected to expand with therapeutic advancements—echoing its founding mission to put cytometry "just a click away" for tomorrow's scientists.[2]
Guava has raised $2.6M in total across 2 funding rounds.
Guava's investors include Niall Santamaria, Tom Williams, Operator Collective, Ed Zimmerman, Edward Zimmerman, Lexi Reese, Backstage Capital, Sydney Paige Thomas, Ruthless for Good Fund.
Guava has raised $2.6M across 2 funding rounds. Most recently, it raised $650K Seed Extension in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 24, 2023 | $650K Seed Extension | Niall Santamaria | |
| Jul 1, 2022 | $2.0M Seed | Tom Williams | Operator Collective, Ed Zimmerman, Edward Zimmerman, Lexi Reese, Backstage Capital, Sydney Paige Thomas, Ruthless for Good Fund |